Swine Vaccines Market Size (2024 - 2029)

The swine vaccines market is projected to experience growth over the forecast period, driven by factors such as government initiatives for swine disease management, increased awareness of influenza A, and heightened research and development efforts towards vaccine innovation. The market's expansion is further supported by the rising incidence of swine fever in developing countries and the efforts of various organizations to manage the disease. Despite the challenges posed by the high costs of storage and potential vaccine reactions, the market is expected to benefit from the developments by key players and the ongoing demand for disease prevention in swine.

Market Size of Swine Vaccines Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Swine Vaccines Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.20 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Swine Vaccines Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Swine Vaccines Market Analysis

The swine vaccines market is expected to register a CAGR of 5.2% over the forecast period.

The COVID-19 pandemic had a substantial impact on the swine vaccine market. The animal health industry witnessed an adverse impact owing to the outbreak of COVID-19. Delays in the delivery of the active ingredients and raw materials and capacity constraints were some of the major concerns that restrained the market's growth during the early pandemic. For instance, according to an article published by the United States Department of Agriculture in February 2022, the COVID-19 pandemic significantly impacted production in pork processing plants across the United States, with effects felt throughout the pork supply chain. Thus, the pandemic had a significant impact on the studied market initially. However, as the pandemic has currently subsided, the studied market is expected to have stable growth during the forecast period of the study.

Factors such as government initiatives toward swine disease management, increasing awareness about influenza A, and an increase in research and development expenditure toward vaccine innovation are expected to boost the market growth.

The increasing cases of swine fever in developing countries and the initiatives by various organizations for the management of the disease are also some of the major factors propelling the market's growth over the forecast period. For instance, as per the report published by the Foundation for Food & Agriculture Research in April 2022, African swine fever (ASF) has emerged as one of the highly contagious viruses that cause 100% mortality in swine. There are no commercially available vaccines to treat the disease. Therefore, in order to combat the disease, the Foundation for Food & Agricultural Research granted USD 145,000 to Genvax Technologies for developing a self-amplifying messenger RNA (saRNA) vaccine for African Swine Fever in association with the United States Department of Agriculture-Agricultural Research Services-Plum Island Animal Disease Center (USDA-ARS-PIADC). African Swine Fever has been detected in many countries until now, except in the United States. In addition, government initiatives toward swine disease management are one of the major factors driving the market growth.

Additionally, according to an article published by Efsa Journal in May 2022, salmonellosis is one of the most common food-borne outbreaks that occurs in the European Union, and it often comes from swine. Thus, the high prevalence of such diseases is expected to enhance the demand for swine vaccines for the prevention of the disease.

Moreover, the development of various market players is also expected to boost market growth. For instance, in December 2022, UConn collaborated with USDA to develop an African swine fever vaccine candidate that is licensed by Zoetis. Similarly, in June 2022, Vietnamese researchers developed a vaccine against African swine fever for pigs in collaboration with the United States.

Therefore, owing to the aforementioned factors, such as the rising developments by key market players, increasing cases of swine fever in developing countries, and the initiatives by various organizations for the management of the disease, the studied market is anticipated to witness growth over the analysis period. However, the high cost of maintaining and handling storage conditions, along with the chance of reverse reactions from vaccines, is likely to impede the market's growth.

Swine Vaccines Industry Segmentation

As per the scope of the report, swine vaccines are generally given to pigs and contain antigens from bacteria, viruses, parasites, or bacterial toxins. It helps to promote an immune response in pigs, which protects against natural infection from which the vaccine has been derived. The swine vaccines market is segmented by product (inactivated vaccines, attenuated live vaccines, recombinant vaccines, and others), disease type (classical swine fever, porcine parvovirus, swine influenza, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD) for the above segments.

By Product
Inactivated Vaccines
Attenuated Live Vaccines
Recombinant Vaccines
Others
By Disease Type
Classical Swine Fever
Porcine Parvovirus
Swine Influenza
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region Or Segment?
Customize Now

Swine Vaccines Market Size Summary

The swine vaccines market is poised for growth, driven by factors such as government initiatives in disease management, heightened awareness of influenza A, and increased investment in research and development for vaccine innovation. The market experienced initial setbacks due to the COVID-19 pandemic, which disrupted supply chains and production, particularly in pork processing plants. However, as these challenges have been addressed, the market is expected to stabilize and expand. The rising incidence of swine fever in developing countries and the efforts by various organizations to manage these diseases are significant contributors to market growth. Notably, the development of vaccines for African swine fever, a highly contagious virus with no commercially available vaccine, underscores the ongoing efforts to combat swine diseases.

The inactivated vaccines segment is anticipated to witness substantial growth, supported by ongoing research and development activities aimed at enhancing their effectiveness against various swine diseases. Collaborations among market players and organizations, such as the United Kingdom Research and Innovation's partnerships in Southeast Asia, further bolster this segment's expansion. North America is expected to hold a significant market share, driven by a high population of hogs and pigs, organized farming structures, and substantial R&D investments. Government initiatives in the region, such as Canada's African swine fever prevention program, also contribute to market growth. The market remains fragmented, with key players like Merck & Co. Inc., Zoetis Inc., and Boehringer Ingelheim GmbH actively participating in the development and launch of new vaccine products.

Explore More

Swine Vaccines Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Government Initiatives toward Swine Flu Management and Increasing Awareness about Influenza A

      2. 1.2.2 Increase In Research and Development Expenditure Toward Vaccine Innovation

    3. 1.3 Market Restraints

      1. 1.3.1 High Expenses of Maintaining and Handling Storage Conditions along with Chance of Reverse Reaction from Vaccines

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Product

      1. 2.1.1 Inactivated Vaccines

      2. 2.1.2 Attenuated Live Vaccines

      3. 2.1.3 Recombinant Vaccines

      4. 2.1.4 Others

    2. 2.2 By Disease Type

      1. 2.2.1 Classical Swine Fever

      2. 2.2.2 Porcine Parvovirus

      3. 2.2.3 Swine Influenza

      4. 2.2.4 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Rest of the World

Swine Vaccines Market Size FAQs

The Global Swine Vaccines Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)

Merck & Co., Inc., Elanco, Boehringer Ingelheim International GmbH, Zoetis Inc. and Ceva Sante Animale are the major companies operating in the Global Swine Vaccines Market.

Swine Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)